Joint Transnational Call for Proposals (2020) for “European Innovative Research & Technological Development Projects in Nanomedicine”

Call is closed!

EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research and innovation programmes with the goal of creating and funding collaborative research and innovation projects that can convert research in nanotechnology into practical gains in medicine. Through 10 successful Joint Transnational Calls launched from 2009 to 2019, EuroNanoMed has allocated about 86 Million euros to fund 100 transnational projects in nanomedicine.

Under the umbrella of EuroNanoMed III, the 11th Joint Transnational Call is launched for funding multilateral innovative research projects on nanomedicine.

  • Opening of the submission system: 5th May 2020
  • Submission deadline of full proposals: 10th June 2020, 17h00 CEST

AIM of the call

EuroNanoMed aims (i) to support translational research projects that combine innovative approaches in the field of nanomedicine and (ii) to encourage and enable transnational collaboration between public and private research groups from academia, clinical/public health research or research teams from industrial enterprises (all size). The participation of Medical Doctors and SMEs will be strongly encouraged.

For more information see the Call text.

TOPICS of the call

Project proposals will address multidisciplinary and translational research. Project proposals will need to cover at least one of the following areas that are equal in relevance for this call:

  1. Regenerative medicine
  2. Diagnostics
  3. Targeted delivery systems

At the end, projects should fall within, but are not limited to, Technology Readiness Levels (TRL)[1] 3-6, although for being realistic and coherent with the characteristics of the call, projects should propose advancements for a maximum of two TRL levels during their lifetime.

[1] Horizon 2020 scale for TRL:

For more information see the Call text.

General conditions for application

A consortium applying to this call will be required to include research group(s) from at least 2 of the 3 following categories, if eligible according to relevant national/regional funding organisations’ regulations for research funding[1]:

  • Academia (research teams working in universities, other higher education institutions or research institutes);
  • Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of Medical Doctors is encouraged;
  • Enterprise (all sizes of private companies). Participation of small and medium-size enterprises (SMEs) will be encouraged.

Only transnational projects will be funded. Each consortium submitting a proposal will need to involve a minimum of 3 eligible and a maximum of 5 eligible partners from at least 3 different countries participating to the call (see list below) though no more than 2 eligible partners from the same country participating in the call will be accepted in one consortium.

Research groups not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding organisation) may participate in transnational projects if they are able to secure their own funding. However, no more than one research group with own funding can be included in a consortium. The coordinator must be eligible to be funded by the participating funding organisations.

The maximum number of partners will possibly be increased from 5 to 7 (including eligible for funding and non-eligible for funding research groups) if partners from these participating countries, whose scientific community has been under-represented in past EuroNanoMed calls: Bulgaria, Czech Republic, Egypt,Estonia, Latvia, Lithuania, Romania, Slovakia, Taiwan and Turkey:

Number of partners requesting funding (eligible partners) 3 4 5 6

(only with at least

one underrepresented)


(only with at least 2 underrepresented)

Possible number of additional partners with own funding 1 1 1 1 0

Please note! Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EuroNanoMed funding organisation respective of the country/region from which applicants have applied. The applications are therefore subject to eligibility criteria of individual funding organisations. Applicants are strongly advised to contact their national representatives as soon as possible in order to confirm their eligibility.

For more information see the Call text.

Looking for partners?

Have a look at the European Nanomedicine Map:

And use the EuroNanoMed partnering tool

Or use any other H2020 NCP Partner-Search Tools here.

Participating countries and regions

Belgium, Bulgaria, Canada (Quebec), Czech Republic, Egypt, Estonia, France, Greece, Israel, Italy, Latvia, Lithuania, Norway, Poland, Romania, Slovakia, Spain, Taiwan and Turkey (see the contact list below).

Please note that funding from Norway will only be eligible to projects in the medical domain of cancer.

Electronic submission website

Research project consortia who intend to submit a transnational proposal should register at, clicking the “to register” button and following the directions. Electronic proposal submission of proposals on the indicated website is mandatory.

Contact details for the Joint Call Secretariat:

JCS is hosted by the French National Research Agency (ANR)
50 avenue Daumesnil, 75012 Paris
Contact persons for the Joint Call Secretariat: Martine BATOUX & Marie-Pierre GOSSELIN
Tel. +33 (0)1 73 54 81 40
Tel. +33 (0)1 78 09 80 38

Call documents:

Call text

Guidelines for applicants

Guidelines for Pre-Clinical and Clinical Studies

Full proposal application form

Contact details of participating members

Country Funding Organisation Contact point Email
Belgium FRS-FNRS Joël Groeneveld
Bulgaria  BNSF Milena Aleksandrova
Canada (Québec) FRQS Maxime Beaudoin
Czech Republic TACR Kristina Nehilčová
Egypt ASRT Amr Radwan
Estonia ETAg Aare Ignat
France ANR Martine Batoux

Marie-Pierre Gosselin
Greece GSRT Paraskevi Afentaki

Anna Rosenberg

Israel CSO-MOH Irit Allon

Orly Spivak

Italy IMH Maria Grazia Mancini

Latvia VIAA Linda Vecbiškena
Lithuania RCL Živilė Ruželė
Norway RCN Cecilie A. Mathiesen
Poland NCBR Marcin Chmielewski
Romania UEFISCDI Mihaela Manole
Slovakia SAS Katarina BIBOVA
Spain AEI Beatriz Gomez
Spain ISCIII Astrid Valencia
Spain CDTI Héctor González
Taiwan MOST Ching-Mei Tang
Turkey TUBITAK Alperen Erdoğan


Call documents

Call text

Guidelines for applicants

Guidelines for Pre-Clinical and Clinical Studies

Full proposal application form



PRP members


  1. Todd Giorgio | Cancer Biology Vanderbilt University, US
  2. Ramaroson ADRIANTSITOHAINA | CHU Angers, France
  3. Eliana BARBOSASOUTO | University of Coimbra, Portugal
  4. María BLANCO-PRIETO | University of Navarra, Spain
  5. Philippe BOURRINET | Guerbet, France
  6. Paolo DECUZZI | Istituto Italiano di Tecnologia, Italy
  7. Sara EYAL | Hebrew University, Israel
  8. Elias FATTAL | Institut Galien, France
  9. César FERNÁNDEZ- SÁNCHEZ | Instituto de Microelectrónica de Barcelona, Spain
  10. Alessandra GENNARI | University Hospital of Novara, Italy
  11. Ireneusz GRUDZINSKI | Medical University of  Warsaw, Poland
  12. Moustapha HASSAN | Karolinska Institutet, Sweden
  13. Ekkehard LEBERER | SANOFI, Germany
  14. Robert LUXENHOFER | University of Würzburg, Germany
  15. Athanasios MANTALARIS | Imperial College London, United Kingdom
  16. Jan MOUS | Pharmida AG, Switzerland
  17. Herman OFFERHAUS | University of Twente, Netherlands
  18. Stefania SCALA | Istituto Nazionale Tumori “Fondazione Pascale”, Italy
  19. Sven SCHREDER | Boehringer Ingelheim Pharma GmbH&Co. KG, Germany
  20. Christopher SCOTT | Queen’s University Belfast, United Kingdom
  21. Alexander SEIFALIAN | University College London, United Kingdom
  22. Jerzy SILBERRING AGH | University of Science and Technology, Poland
  23. Stephan STERN | National Cancer Institute, USA
  24. Meritxell TEIXIDÓ TURÁ | Institute for Research in Biomedicine, Spain
  25. Iwona WYBRANSKA | Jagiellonian University, Poland